Cel-Sci Corporation (CVM) financial statements (2021 and earlier)

Company profile

Business Address 8229 BOONE BLVD .
VIENNA, VA 22182
State of Incorp. CO
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments221620149
Cash and cash equivalents221620149
Receivables00000
Inventory, net of allowances, customer advances and progress billings11111
Inventory11111
Prepaid expense11210
Total current assets:2418231611
Noncurrent Assets
Finance lease, right-of-use asset1314141513
Operating lease, right-of-use asset11111
Property, plant and equipment96433
Intangible assets, net (including goodwill)00000
Intangible assets, net (excluding goodwill)00000
Other undisclosed noncurrent assets(23)(19)(20)22
Total noncurrent assets:2202119
Other undisclosed assets242121  
TOTAL ASSETS:5041443730
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities43112
Accounts payable32111
Accrued liabilities11000
Debt0    
Derivative instruments and hedges, liabilities20221
Due to related parties00111
Other liabilities   00
Other undisclosed current liabilities11111
Total current liabilities:74555
Noncurrent Liabilities
Long-term debt and lease obligation1313131313
Finance lease, liability1112121212
Operating lease, liability11111
Liabilities, other than long-term debt14545
Other liabilities00000
Derivative instruments and hedges, liabilities14545
Total noncurrent liabilities:1317181718
Total liabilities:2121232323
Stockholders' equity
Stockholders' equity attributable to parent, including:292021147
Common stock00000
Common stock, share subscribed but unissued, subscriptions receivable  (0)(0) 
Additional paid in capital418401397380366
Accumulated deficit(390)(382)(376)(366)(359)
Other undisclosed stockholders' equity attributable to parent  00 
Total stockholders' equity:292021147
TOTAL LIABILITIES AND EQUITY:5041443730

Income statement (P&L) ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
Net investment income0    
Other income 0000
Gross profit:00000
Operating expenses(9)(8)(7)(7)(7)
Other undisclosed operating loss(0)    
Operating loss:(9)(8)(7)(7)(7)
Nonoperating income (expense)00(2)11
Investment income, nonoperating00(2)11
Interest and debt expense (1)(0)  
Loss from continuing operations before equity method investments, income taxes:(9)(10)(9)(6)(6)
Other undisclosed income from continuing operations before income taxes14   
Net loss:(8)(5)(9)(6)(6)
Other undisclosed net income (loss) attributable to parent  (1)(3)1
Net loss attributable to parent:(8)(5)(10)(9)(5)
Other undisclosed net loss available to common stockholders, basic(0)  (0) 
Net loss available to common stockholders, diluted:(8)(5)(10)(9)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
Net loss:(8)(5)(9)(6)(6)
Comprehensive loss, net of tax, attributable to parent:(8)(5)(9)(6)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: